Drugs / REGN13335
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06137482 | Dec 2023 → Feb 2025 | — | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07318597 | May 2026 → Feb 2028 expected | pulmonary arterial hypertension | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | REGN13335 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07318597 ↗ |
| Action | Inhibit | “a Platelet-Derived Growth Factor-B Antagonist” NCT06137482 ↗ |
| Modality | Monoclonal antibody | “an Anti-PDGF-B Monoclonal Antibody” NCT07318597 ↗ |
| Route | Intravenous | “Administered intravenous (IV) or subcutaneous (SC)” NCT06137482 ↗ |
| Route | Subcutaneous | “Administered intravenous (IV) or subcutaneous (SC)” NCT06137482 ↗ |
| Target | PDGFB | “Anti-PDGF-B Monoclonal Antibody” NCT07318597 ↗ |